Abstract
Background: Parthenolide (PN) has been reported to inhibit proliferation and induces apoptosis in a variety of cancer cells with different mechanisms. Nevertheless, to the best of our knowledge, its relative anticancer activity at lower doses has not been reported in HaCaT immortalized keratinocytes and A375 melanoma cells.
Objective and Method: The present study aimed to investigate the relative anticancer effects of PN by analysing its cytotoxicity, apoptosis and cell cycle arresting potentials in HaCaT and A375 cells.
Result: PN was found to be significantly cytotoxic with lower IC50 values of 1.45 µM and 2.9 µM (p<0.05) in HaCaT and A375 cells, respectively with nuclear disruption as evident by DAPI staining. A dose-dependent increase in DNA fragmentation indicated apoptotic cell death. Furthermore, the percentage of cells deposition at S (35.56 to 43.68%) and G0-G1 (27.15 to 56.44%) phases after 24 h of PN treatment, substantiate its cell cycle arresting potentials in HaCaT and A375 cells.
Conclusion: These comparative results provided substantial evidence to conclude the anticancer potential of PN, especially at lower dosages to induce cell death mechanisms in skin epidermal cells.
Keywords: Apoptosis, cell cycle arrest, DNA fragmentation, keratinocytes, melanoma, parthenolide.
Current Drug Discovery Technologies
Title:Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Volume: 13 Issue: 1
Author(s): Vazhappilly C. George, Devanga R.N. Kumar and Rangasamy A. Kumar
Affiliation:
Keywords: Apoptosis, cell cycle arrest, DNA fragmentation, keratinocytes, melanoma, parthenolide.
Abstract: Background: Parthenolide (PN) has been reported to inhibit proliferation and induces apoptosis in a variety of cancer cells with different mechanisms. Nevertheless, to the best of our knowledge, its relative anticancer activity at lower doses has not been reported in HaCaT immortalized keratinocytes and A375 melanoma cells.
Objective and Method: The present study aimed to investigate the relative anticancer effects of PN by analysing its cytotoxicity, apoptosis and cell cycle arresting potentials in HaCaT and A375 cells.
Result: PN was found to be significantly cytotoxic with lower IC50 values of 1.45 µM and 2.9 µM (p<0.05) in HaCaT and A375 cells, respectively with nuclear disruption as evident by DAPI staining. A dose-dependent increase in DNA fragmentation indicated apoptotic cell death. Furthermore, the percentage of cells deposition at S (35.56 to 43.68%) and G0-G1 (27.15 to 56.44%) phases after 24 h of PN treatment, substantiate its cell cycle arresting potentials in HaCaT and A375 cells.
Conclusion: These comparative results provided substantial evidence to conclude the anticancer potential of PN, especially at lower dosages to induce cell death mechanisms in skin epidermal cells.
Export Options
About this article
Cite this article as:
George C. Vazhappilly, Kumar R.N. Devanga and Kumar A. Rangasamy, Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells, Current Drug Discovery Technologies 2016; 13 (1) . https://dx.doi.org/10.2174/1570163813666160224124029
DOI https://dx.doi.org/10.2174/1570163813666160224124029 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy (Part II)
Current Gene Therapy RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Kidney Diseases and Chemokines
Current Drug Targets Death Receptor Ligands: New Strategies for Combined Treatment with Ionizing Radiation
Current Medicinal Chemistry - Anti-Cancer Agents Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Brain Perfusion SPECT with Brodmann Areas Analysis in Differentiating Frontotemporal Dementia Subtypes
Current Alzheimer Research Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy